NCT07170475 - A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 27, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

July 31, 2026

Conditions

Parkinson's Disease (PD)

Interventions

DRUG

Febuxostat

Febuxostat tablets (per randomized assignment), administered orally twice daily (once in the morning and once in the evening) for 12 weeks.

DRUG

Inosine

Inosine tablets (per randomized assignment), administered orally twice daily (once in the morning and once in the evening) for 12 weeks.

Trial Locations (1)

RECRUITING

Fujita Health University, Toyoake

All Listed Sponsors

lead

Fujita Health University

OTHER